Plain-English translation of NCT04372108 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn Disease research guide →This study is comparing the long-term safety of with other biologic medications used to treat Crohn's disease and ulcerative colitis. Researchers will look at medical records from military health systems to see how often serious problems—like cancer, serious infections, or rare infections—happen in people taking this medication compared to those taking other biologic treatments. The goal is to help doctors understand which treatments are safest over time.
Biologic medications help many people with bowel disease, but doctors need good information about their safety over many years. This study will help answer important questions about whether this medication is safer or carries different risks compared to other biologic options available today.
You likely qualify if…
You likely don't qualify if…
This is not a study where you take a new medication or visit a clinic. Instead, researchers will review your existing military health records to track your health over time. They will look at what medications you take, any infections or health problems you develop, and compare your outcomes with others taking different biologic treatments. Your participation involves allowing researchers to access and analyze your electronic health records—no visits, blood draws, or new treatments required.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States
Sponsor
Janssen Scientific Affairs, LLC
Enrollment target
~1,536 participants
Started
June 2021
Primary completion
August 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Contact
Janssen Scientific Affairs, LLC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.